(Q46308859)

21 December 2017

title

Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis (English)

1 reference

21 December 2017

0 references

1 reference

B G Vickrey

1 reference

21 December 2017

R D Hays

1 reference

21 December 2017

B J Genovese

1 reference

21 December 2017

L W Myers

1 reference

21 December 2017

G W Ellison

1 reference

21 December 2017

publication date

1 May 1997

1 reference

21 December 2017

Journal of Clinical Epidemiology

published in

1 reference

21 December 2017

volume

1 reference

21 December 2017

issue

1 reference

21 December 2017

page(s)

557-569

1 reference

21 December 2017

Disease-specific versus generic measurement of health-related quality of life in insulin-dependent diabetic patients

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

Self-assessed health and use of health services

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

Comparison of patient and staff assessment of MS patients' health status.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

The RAND 36-Item Health Survey 1.0.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

The MOS short-form general health survey. Reliability and validity in a patient population

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

The Medical Outcomes Study. An application of methods for monitoring the results of medical care

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

Multitrait-multimethod analysis of health-related quality-of-life measures

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

Functional disability assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

The Functional Status Questionnaire: reliability and validity when used in primary care.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

Coefficient alpha and the internal structure of tests

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

Quality of life of epilepsy surgery patients as compared with outpatients with hypertension, diabetes, heart disease, and/or depressive symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900001-2

7 January 2021

10.1016/S0895-4356(97)00001-2

Identifiers

DOI

1 reference

21 December 2017

1 reference

21 December 2017